期刊文献+

神经营养素4前导序列介导Exendin-4表达质粒的构建及鉴定 被引量:3

Identification and Construction of Plasmid Expressing Exendin-4 Mediated NT4 Leading Sequence
下载PDF
导出
摘要 目的:构建神经营养素4前导序列介导的可分泌表达Exendin-4的重组腺伴病毒载体,为探究Exendin-4用于2型糖尿病临床治疗提供实验基础。方法:使用互补引物/模板法及T载体克隆法扩增Exendin-4的cDNA克隆,连接于NT4前导肽序列的3′端,融合基因NT4-Exendin-4亚克隆于穿梭质粒pSSHG,转染HEK-293细胞,包装病毒,斑点杂交方法测定重组病毒滴度。结果:经酶切、测序证实克隆出Exendin-4 cDNA,成功构建同一开放读码框ORF的NT4前导肽Exendin-4 cDNA克隆,得到高滴度(2.5×109pfu·L-1)的重组腺相关病毒。结论:通过分子克隆技术成功制备了Exendin-4的重组腺伴病毒载体pSSHG/NT4-Exendin-4并成功包装了较高浓度的重组病毒,为进一步研究Exendin-4功能及应用于临床打下基础。 Objective:To identify and construct a recombinant adeno-associated virus(AAV) vector that can secrete Exendin-4 mediated by NT4 leading sequence. Methods:Exendin-4 cDNA was cloned by complementary primer/template PCR and T carrier cloning method. The Exendin-4 gene was linked to terminal of the signal peptide of NT4 leading sequence. The fusion gene of NT4- Exendin-4 was subcloned into the shuttle plasmid of pSSHG. The recombinant virus was transfected and packaged by human embryo kidney 293 cells and the virus titer was measured by quantitative dot-blot hybridization. Results:Exendin-4 cDNA cloning was confirmed by restriction enzyme digestion and DNA sequencing. The NT4 leading sequence and Exendin-4 cDNA clone were successful constructed in the same ORF and high titer of recombinant AAV was obtained(2.5×109pfu·L-1). Conclusion:The recombinant virus pSSHG/NT4-Exendin-4 was successfully constructed by molecular cloning. The relatively high levels of recombinant virus were obtained. These results provide the basis for further studies that examine the function of Exendin-4.
出处 《神经药理学报》 2012年第3期22-28,共7页 Acta Neuropharmacologica
基金 陕西省社发攻关项目(No.2011K14-06-04)
关键词 质粒构建 EXENDIN-4 NT4 腺伴病毒载体 plasmid construction Exendin-4 NT4 adeno-associated virus(AAV)
  • 相关文献

参考文献3

二级参考文献15

  • 1金冬雁 黎孟枫等(译).分子克隆实验指南(第二版)[M].北京:科学出版社,1996..
  • 2Gozes I. Neuroprotective peptide drug delivery and development:potential new therapeutics (review). Trends Neurosci, 2001, 24: 700-705.
  • 3Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Neurochem, 1999, 72: 1283-1293.
  • 4Zamostiano R, Pinhasov A, Gelber E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein.J Biol Chem, 2001, 276: 708-714.
  • 5Leker RR, Teichner A, Grigoriadis N, et al. NAP, a femtomolar-activity peptide protects the brain against ischemic injury by reducing apoptotic death. Stroke, 2002, 33: 1085-1092.
  • 6Nathan DM, Buse JB, Davidsen MB,et al. Medical management of hy-perglycemia in type 2 diabetes:a consensus algorithm for the initia-tion and adjustment of therapy : a consensus statement of the Ameri-can Diabe tes Association and the European Association for the studyof Diabetes [J]. Diabetes Care,2009,32: 193—203.
  • 7Parkes DG, Mace KF ,Trautmann ME. Discovery and development ofexenatide : the first antidiabetic agent to leverage the multiple bene-fits of the incretin hormone,GLP-1 [J]. Expert Opin Drug Discov,2013,8(2):219-244.
  • 8Goke R,Fehmann HC,Linn T,et al. Exendin-4 is a high potency ag-onist and truncated exendin -(9 -39) -amide an antagonist at theglucagon-like peptide 1-(7-36)-amide receptor of insulin secretingbeta-cells [J]. J Biol Chem, 1993,268(26): 19650-19655.
  • 9Nielsen LL,Young AA,Parkes DG. Pharmacology of exenatide (syn-thetic exendin-4) :a potential therapeutic for improved glycemic con-trol of type 2 diabetes [J].Regul Pept ,2004,117(2) :77-88.
  • 10Sambrook J,Fritsch EF,Maniatis T. Molecular cloning: a laboratorymanual[M].北京:科学出版社,1999:34-66,237-325.

共引文献16

同被引文献63

  • 1Russell S. Incretin-based therapies for type 2 diabetes mellitus:a review of direct comparisons of efficacy, safety and patient satisfac-tion[J]. Int J Clin Pharm,2013,35(2):159-172.
  • 2Parkes, D G, Mace K F, Trautmann M E. Discovery and development of exenatide:the first antidiabetic agent to leverage the multiple ben-efits of the incretin hormone, GLP-1 [J]. Expert Opin Drug is-cov,2013,8(2):219-244.
  • 3Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initi-ation and adjustment of therapy:a consensus statement of the Ameri-can Diabetes Association and the European Association for the Study of Diabetes [J]. Diabetes Care,2009,32 (1):193-203.
  • 4Pinto D1, Heleno B, Gallego R,et al. Guideline:type 2 diabetes mellitus therapy:mefformin, a critical perspective [J]. Acta Med Port,2011, 24 (2):331-338.
  • 5Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease [J]. Clin Sci (Lond) ,2013,124 (1):17-26.
  • 6Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab,2003,88 (7):3082-3089.
  • 7Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus[J]. Ann Pharma-cother,2012,46 (6):812-821.
  • 8Parkes D G, Mace K F, Trautmann M E. Discovery and development of exenatide:the first antidiabetic agent to leverage the multiple ben-efits of the incretin hormone, GLP-1 [J]. Expert Opin Drug Dis-cov,2013,8(2):219-244.
  • 9Davies MJ, Donnelly R, Barnett All, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes:resp~lts of the Helping E-valuate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study [J]. Diabetes Obes Metab,2009,11 (12):1153-1162.
  • 10Bunck MC, Corner A, Eliasson B, et al. 2011 Effects of exenatide on measures of beta-cell function after 3 years in mefformin-trea-ted patients with type 2 diabetes [J]. Diabetes Care, 2011,34 (9): 2041-2047.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部